Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Sanofi logo at the company's headquarters during the annual results news conference in Paris (Reuters) -Sanofi won ...
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) on Friday announced that the U.S. Food and Drug Administration (FDA) has approved their Dupixent injection for the treatment of adult patients ...
July 3 (Reuters) - Sanofi (SASY.PA), opens new tab and partner Regeneron (REGN.O), opens new tab on Wednesday won European Union approval for wider use of their Dupixent injection in patients with a ...
Dupixent is a prescription injection that treats several conditions, including eczema, asthma, COPD, and rhinosinusitis. A copay card may assist you with Dupixent’s cost. Dupixent is a brand-name ...
Targeted treatments have emerged as a safer and more effective option for eczema patients, but high costs remain a barrier.
TORONTO, Oct. 22, 2025 /CNW/ - Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) ...
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved ...
Sanofi, Inc.SNY and partner Regeneron Pharmaceuticals, Inc. REGN announced that a phase II study evaluating its injection Dupixent for the treatment of adults with active moderate-to-severe ...
(Reuters) - The U.S. Food and Drug Administration on Wednesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug Dupixent to treat nasal polyps, marking the third major use for the ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Dupixent injection to treat adults with moderate-to-severe atopic dermatitis whose disease ...
Sanofi and Regeneron Pharmaceuticals drug Dupixent has won FDA approval for chronic spontaneous urticaria, introducing a new approach to the treatment of this inflammatory skin disorder. It’s the ...
WASHINGTON -- The FDA approved the biologic drug dupilumab (Dupixent) for adults with moderate to severe atopic dermatitis, or eczema, that is not controlled with topical treatments or who need a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results